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Abstract
Over the last several decades Quality of Life (QoL) has become increasingly important as an 
indicator of treatment outcomes; particularly in schizophrenia spectrum disorders because of its 
close association with functional disability. Numerous studies seeking to elucidate the factors that 
contribute to QoL in this population have implicated both symptom severity and cognition in 
determining QoL but the findings have been mixed. The critical factors that appear to impede the 
lack of consensus in the extant literature examining determinants of QoL include the heterogeneity 
of the samples and measures examined as well as medication effects across different studies. Thus, 
the present study sought to address some of these issues by examining the relationship between 
subjective QoL and both symptom severity and cognitive function in a relatively homogeneous 
patient sample of patients and a community control sample assessed for dimensional symptom 
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severity. Our results suggest that both global cognitive function and psychiatric symptoms have a 
significant impact on the subjective QoL of both people with schizophrenia spectrum disorders 
and psychiatrically healthy adults. Specifically, we found that a global index of cognition as well 
as self-reported avolitional and depressive symptoms were significantly predictive of QoL in both 
samples. These findings highlight the importance of addressing cognitive, depressive and 
avolitional symptoms in the treatment of patients with schizophrenia spectrum disorders and 
suggest that improvements in these domains may have a meaningful impact on their overall QoL.
Keywords
Quality of Life; QoL; cognition; negative symptoms; depression; MCCB
1. Introduction
Quality of Life (QoL) is a multidimensional construct encompassing an individual’s 
perception of their position in life in relation to their culture, goals, expectations, standards 
and concerns (WHOQOL-Group, 1995). Over the last several decades QoL has become 
increasingly important as an indicator of treatment outcomes over a wide range of health and 
disease states. This interest in QoL as an outcome measure has been particularly pronounced 
in schizophrenia spectrum disorders (SZ) because of its close association with functional 
disability; a critical problem for patients with these disorders (Lieberman et al., 2008; Malla 
and Payne, 2005).
To date, numerous studies of people with SZ have implicated general psychopathology such 
as anxiety and depressive symptoms (Dickerson et al., 1998; Huppert et al., 2001; Narvaez et 
al., 2008; Reine et al., 2003) as well as the more specific domains of positive and negative 
symptoms (Fitzgerald et al., 2001; Norman et al., 2000; Savill et al., 2016) in determining 
QoL. A recent meta-analysis (Eack and Newhill, 2007) examining the relative contribution 
of psychiatric symptoms to QoL found that these symptoms have a significant, but small, 
negative relationship with QoL in patients with SZ. However, these authors acknowledged 
that their results were limited by the heterogeneity among the samples included noting that 
sample characteristics such as treatment setting (inpatient vs. outpatient) and illness stage 
(first-episode vs. chronic), which were commonly intermixed in a given sample, had 
systematic effects on the observed interaction between QoL and psychiatric symptoms. 
Thus, they argued that a more concise understanding of the relationship between QoL and 
symptoms would require the study of more homogeneous samples.
Numerous studies have also implicated cognitive functioning in variation in QoL among 
patients with SZ, although these studies have also produced conflicting results. While some 
studies have found positive relationships (Savilla et al., 2008; Ritsner 2007; Alptekin et al., 
2005; Herman 2004) others have found negative relationships (Brekke et al 2001; Dickerson 
et al., 1998; Narvaez et al 2008) and yet others have found no relationship (Brissos et al 
2005; Chino et al 2009; Hofer et al 2005; Smith et al 1999). Similar to the findings 
examining the relation between QoL and symptoms, however, data derived from a recent 
meta-analysis of the relation between QoL and cognition (Tolman and Kurtz, 2012) also 
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suggests that methodological differences are likely hindering consensus about the nature of 
the relationship. This meta-analysis indicated that cognition had a moderate effect on 
measures of objective QoL, which is typically clinician rated, but no effect on subjective 
QoL, which is typically self-reported. However, similar to the prior meta-analysis on the 
relation between symptoms and QoL, Tolman and Kurtz (2012) concluded that the 
intermixing of samples with different clinical characteristics was likely impacting this latter 
finding, which was found to be statistically unstable.
One critical issue that was not addressed by either of the aforementioned meta-analyses was 
the specific way in which subjective QoL was measured. Although both studies 
differentiated between objective and subjective QoL, a critical distinction given that they are 
only modestly correlated (Sainfort et al. 1996; Kusel et al. 2007; Bengtsson-Tops et al. 
2005), they did not differentiate between general and population-specific measures of 
subjective QoL. For example, subjective QoL in patients with SZ is commonly measured 
using the Quality of Life Interview (Lehman 1988), which was specifically designed for 
people with serious mental illness and thus, assesses what is deemed clinically relevant in 
this population and is not typically viewed as valid for measuring QoL in non-psychiatric 
populations. More recent studies however, have begun to employ more general scales such 
as the World Health Organization Quality of Life Assessment (WHOQOL) that are valid in 
both patient and healthy samples. These more general scales appear to be less sensitive to 
variations in the characteristics of a specific illness such as SZ (Orsel et al. 2004) and thus, 
may reflect a more comprehensive assessment of QoL. In both aforementioned meta-
analyses, studies using both population-specific and general measures of QoL were 
examined collectively resulting in perhaps an even more turbid understanding of the relation 
between clinical factors and subjective QoL.
Notably, prior work has also found that antipsychotic medications, which have a wide range 
of effects on both symptoms and cognitive function as well as a range of adverse effects, 
also contribute to variation in QoL in SZ patients. For example, Ritsner et al (2004) found 
that in a group of patients whose symptoms were stabilized on an antipsychotic medication, 
those patients who were experiencing adverse events reported significantly lower QoL than 
those who were not experiencing adverse events. Moreover, a recent randomized controlled 
trial found that patients taking second generation antipsychotic medications experienced a 
significantly greater improvement in subjective QoL than those taking first generation 
agents; an effect that the authors partially attributed to fewer adverse events. Thus, the study 
of an unmedicated sample examined in parallel to the medicated patient sample might lead 
to a better understanding of how both symptom severity and cognitive function relate to 
subjective QoL.
In addition to these methodological complications, recent work has stressed the need for a 
more dimensional view of the negative symptom construct. Factor analytic studies have 
consistently demonstrated that negative symptoms can be separated into two broad 
dimensions: a motivational dimension consisting of avolition, anhedonia and asociality and 
an expressivity dimension consisting of blunted affect and alogia (Blanchard and Cohen, 
2006; Kirkpatrick et al., 2006; Kring et al., 2013). While both of these dimensions may be 
critical to functional outcomes, data suggests that deficits in the motivational dimension have 
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the greatest effects on functional disability. For example Foussias et al. (2009) found that 
motivational deficits accounted for 74% of the variance in functional disability in SZ 
patients, with no additional contribution of deficits in expressivity. Notably, the only study to 
date that has sought to assess the differential contribution of dimensional measures of 
negative symptoms to patients’ subjective QoL found that QoL was exclusively related to 
motivational deficits (Savill et al., 2016). Thus, given the relationship between functional 
disability and QoL, examination of the role of these two facets of negative symptoms as 
determinants of QoL seems timely.
The present study aimed to examine the relationship between subjective QoL and both 
symptom severity and neurocognitive function in 2 distinct samples that varied across a 
spectrum of symptom severity including a general population sample and a patient sample. 
Our approach allowed us to address several of the limitations of previous studies. Most 
notably, in an effort to address limitations of previous work involving the intermixing of 
sample characteristics including early vs. chronic illness and inpatient vs. outpatient 
treatment setting, we examined a relatively homogenous group of chronic patients with SZ 
being treated in an outpatient setting for at least six months. Given that subjective QoL 
represents how a person feels about their “position in life”, we believe that this latter criteria 
is critical. Patients who are, or were in the recent past, hospitalized at the time of assessment 
not only have limited control over their daily lives, but they are also unlikely to feel positive 
about it. Additionally, to address concerns related to the effects of medication status, we 
examined these relationships using identical measures in a sample of community controls 
who did not have a psychiatric diagnosis and were not taking any psychotropic medication. 
Finally, to address the specific effects of different dimensions of negative symptom on QoL, 
measures encompassing both the motivational and expressivity dimensions were examined.
2. Method
2.1 Participants
The sample was comprised of 149 chronic, stable outpatients with schizophrenia or 
schizoaffective disorder (95 males, 54 females; MIllness Duration = 14.42 ± 4.86 years) and 
408 healthy adult volunteers (133 males, 275 females). Patient participants were recruited 
from the Zucker Hillside Hospital (ZHH), a division of Northwell Health, for an NIMH-
funded study on functional outcome in schizophrenia (MH079800 to AKM). Patient 
participants were excluded from the study if they had a psychiatric hospitalization within the 
preceding 6 months, met diagnostic criteria for current substance abuse (within the past 
month), or had a history of CNS trauma, neurological disorder or intellectual disability. 
Healthy volunteers were recruited from the general population via word of mouth, 
newspaper and internet advertisements and posted flyers for an NIMH-funded study of 
subclinical psychopathology (MH086756 to PD). Healthy participants were excluded from 
the study if they had an Axis I affective or psychotic disorder diagnosis, active or recent 
substance abuse (as determined by urine toxicology) or any disorder known to affect the 
brain. The patient and control samples used in the present study represent subsets of larger 
samples and were selected based on the availability of data from the self-report measures 
used in the analyses. The limited availability of the self-report data was due to the late 
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addition of these measurements to the assessment schedules of these studies. All participants 
provided written informed consent to a protocol approved by the Institutional Review Board 
of Northwell Health.
2.2 Clinical Assessments
2.2.1 Diagnostic Interviews—Patient participants were administered the Structured 
Clinical Interview for the DSM-IV Axis I Disorders, Patient edition(SCID-I/P) (First et al., 
1995b) by Ph.D. or Master’s level psychometricians. Information obtained from the SCID 
was supplemented by a review of medical records and interviews with family informants, 
whenever possible, and compiled into a narrative case summary. Diagnoses were then 
determined by a consensus among a minimum of three senior ZHH faculty, after a thorough 
review of the SCID and the corroborating information comprising the narrative case 
summary. Healthy participants were initially administered the Structured Clinical Interview 
for the DSM-IV, Non-Patient edition (SCID-I/NP) (First et al., 1995a) by Ph.D. or Master’s 
level psychometricians. Information obtained from the SCID was compiled into a narrative 
case summary and absence of pathology was determined by consensus among two senior 
members of the ZHH faculty.
2.2.2 Assessment of Psychopathology—All participants were assessed using the 
Community Assessment of Psychic Experiences (CAPE) (Stefanis et al., 2002). The CAPE 
is a 42-item, self-report questionnaire that measures three dimensions of subclinical 
psychopathology including positive, negative and depressive symptoms. The CAPE provides 
scores on each of the three dimensions as well as a total score representing the overall 
severity of symptoms. The present study sought to assess the differential effects of specific 
symptom domains on subjective QoL, with a particular focus on negative symptoms. Thus, 
although we utilized the standard positive and depressive subscale scores we used the more 
specific negative symptom subscales described by Barragan et al. (2011), which includes 
subscale scores for social withdrawal, affective flattening and avolition.
Patient participants were also assessed using standard clinician-administered rating scales to 
assess symptom severity during the week preceding the interview. These scales included the 
Brief Psychiatric Rating Scale (BPRS-Hillside version) (Woerner et al., 1988), the Scale for 
the Assessment of Negative Symptoms (SANS-Hillside version) (Robinson et al., 2000) and 
the 24-item Hamilton Rating Scale for Depression (HRSD-24) (Hamilton, 1967). These 
assessments were completed the same day as the CAPE. All clinician-administered scales 
were administered by Ph.D. or Master’s level psychometricians. Inter-rater reliability on all 
measures, assessed annually using gold standard videotaped interviews, was high (all 
Kappa’s > .80).
2.2.3 Assessment of Quality of Life—To assess subjective QoL, we administered the 
Quality of Life Scale (QOLS) (Burckhardt and Anderson, 2003), a 16-item self-report 
measure that assesses six conceptual domains of quality of life including: 1) material and 
physical well-being, 2) relationships with other people, 3) social, community and civic 
activities, 4) personal development, 5) fulfillment and recreation and 6) independence. The 
QOLS is a reliable and well-validated instrument for measuring QoL from the perspective of 
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patients with chronic illness. Critical to the present study, and in contrast to quality of life 
measures typically used in patients with schizophrenia however, it is also well validated in 
samples of healthy individuals and has been shown to produce similar scores across different 
age, sex and racial groups (Burckhardt and Anderson, 2003). The QOLS is scored by adding 
up the score on each item to yield a total score ranging from 16 to 112 with higher scores 
indicating a better quality of life.
2.3 Neurocognitive Assessment
To assess neurocognitive functioning, The MATRICS Consensus Cognitive Battery (MCCB) 
was administered to all participants. The MCCB is comprised of 10 standardized cognitive 
measures that capture functioning within seven cognitive domains that are most related to 
psychotic disorders (Nuechterlein et al., 2008). Although the MCCB provides scores on a 
range of cognitive domains, in the present study we only used the MCCB Composite score, 
which provides an index of global cognitive ability.
2.4 Statistical Analysis
To examine the contribution of self-rated positive, negative and depressive symptoms to 
subjective QoL we carried out two multiple linear regressions; one in patients and one in 
healthy volunteers, which both employed the same structure. We utilized a block-wise 
approach to determine the amount of variance in subjective QoL that could be accounted for 
by global cognitive function and self-reported symptom severity above and beyond the 
effects of sex and age. Thus, a three-block model was employed in which the first block 
examined only the effects of age and sex on QoL, the second block included the Composite 
Score derived from the MCCB and the final block included the overall severity of self-
reported symptoms including, positive, depressive, and three domains of negative symptoms 
(social withdrawal, flat affect, avolition).
3. Results
3.1 Demographics
Comparison of demographic characteristics between patients and healthy volunteers 
revealed significant differences in the distributions of males and females as well as the 
distribution of racial groups. Specifically, the group of healthy volunteers had a significantly 
higher proportion of females and fewer minorities than the patient group. These data are 
shown in Table 1. Consistent with our prior results (DeRosse et al., 2014b), scores on the 
CAPE were not normally distributed for either patients or healthy volunteers and thus, 
comparisons on these measures were carried out using Mann-Whitney U tests. QOLS as 
well as MCCB Composite scores were normally distributed in both groups and comparisons 
were conducted using t-tests. As expected, patients scored significantly higher on all CAPE 
subscales, lower on MCCB Composite score and lower on the QOLS. These results are also 
shown in Table 1.
3.2 Healthy Volunteers
In healthy volunteers, the full regression model accounted for 31% of the variance in QOLS 
scores (R2=0.31; (F(8, 119)=7.72, p<.001). The final block of the model, which assessed the 
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effects of self-reported symptoms above and beyond sex, age and MCCB Composite score, 
demonstrated a significant increase in the variance previously accounted for by age, sex and 
MCCB Composite alone (R2 change =0.34; F(5, 111)=11.78, p<.001). In the final model, the 
specific predictors included MCCB Composite score, self-reported positive symptoms, self-
reported depressive symptoms, self-reported social withdrawal and self-reported avolitional 
symptoms. These results are shown in Table 2.
3.3 Patients
Similarly, the full regression model in patients accounted for 27% of the variance in QOLS 
scores (R2=0.27; (F(8, 112)=6.47, p<.001) and the final block of the model demonstrated a 
significant increase in the variance previously accounted for by age, sex and MCCB 
Composite alone (R2 change =0.21; F(5, 112)=6.86, p<.001). The final model in patients 
indicated that the specific predictors of QOLS level included MCCB Composite score, self-
reported depressive symptoms and self-reported avolitional symptoms. These results are 
shown in Table 2. Additionally, Figure 1 illustrates the relationship we observed between 
those predictors of QOLS scores that overlapped in both the patient and healthy volunteer 
samples.
Although we have previously demonstrated that patients self-reported symptoms are 
significantly correlated with scores on clinician administered assessments of the same 
symptom constructs (DeRosse et al., 2014b), it is not clear if scores derived from clinician-
administered symptom assessments will relate to subjective QoL in the same way as self-
reported symptoms. Thus, to address this question, we repeated the primary regression 
analysis in patients using the HRSD-24 total score in place of the CAPE depressive 
symptom score, the BPRS Psychosis Factor score in place of CAPE positive symptoms and 
the Global SANS scores for affective flattening, avolition and anhedonia in place of the 
CAPE negative symptom subscales. The results of this analysis were similar to, although not 
entirely consistent with, the results using self-reported measures of symptom severity. 
Notably, although we found that the final model using clinician-assessed symptoms was also 
significant and accounted for 25% of the variance in QOLS scores (R2=0.25; (F(8, 111)=5.63, 
p<.001) the specific predictors only included age, MCCB Composite score and HRSD Total 
score; clinician-assessed symptoms of avolition in this model were not significantly 
predictive of QOLS scores. These results are shown in Table 2.
4. Discussion
The results of the present study suggest that both global cognitive function and psychiatric 
symptoms have a significant impact on the subjective QoL of both people with 
schizophrenia spectrum disorders and psychiatrically healthy adults. Specifically, we found 
that a global index of cognition as well as self-reported avolitional and depressive symptoms 
were significantly predictive of QoL in both of our samples. These findings are generally 
consistent with prior work in patients indicating that depressive symptoms (Dickerson et al., 
1998; Huppert et al., 2001; Narvaez et al., 2008; Reine et al., 2003) and motivational deficits 
(Fitzgerald et al., 2001; Norman et al., 2000; Savill et al., 2016) are among the strongest 
predictors of subjective QoL. Moreover, the consistency in the pattern of results relating 
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depressive and avolitional symptoms to subjective QoL across both groups suggest that these 
effects are not attributable to medication effects as none of the community controls in the 
present sample were taking psychotropic medications. Finally, at a general level, the similar 
pattern observed in both patient and control samples are consistent with the contemporary 
view of psychopathology, including psychotic experiences, as dimensional rather than 
dichotomous constructs (van Os, 2010).
Examined independently, the findings in the control sample suggest that while subclinical 
avolitional symptoms are the strongest predictors of QoL, virtually all domains of 
subclinical symptoms are predictive of QoL in this population. Although this finding is 
consistent with prior work in this population (Cohen & Davis, 2009), it is somewhat 
surprising in that it is not consistent with what we observed in the patient sample. However, 
it is likely that the discrepant findings are due less to differences in the actual relationships 
and more to our statistical power to detect them. Table 2 clearly indicates similar 
relationships in both samples and given the 2.5 fold increase in the control sample (N=408) 
relative to the patient sample (N=149), this interpretation is likely. Thus, additional work 
with larger patient samples is needed.
Surprisingly, although we found that global cognitive function was significantly associated 
with subjective QoL in both patient and healthy volunteer groups, the direction of this 
relationship differed between groups. In healthy volunteers lower global cognitive function, 
whereas in patients, higher global cognitive function, predicted a significantly worse 
subjective QoL. Given prior work in this area suggesting a positive relationship between 
cognitive function and QoL (Alptekin et al., 2005; Ritsner, 2007) as well as the substantial 
literature linking better cognition to better longitudinal outcomes (Green et al., 2004) our 
finding was unexpected. However, there are several reports in the literature that are directly 
consistent with our finding (Hofer et al., 2005; Narvaez et al., 2008) and in retrospect, this 
relationship may be somewhat intuitive. Specifically, patients with relatively intact cognitive 
functioning may be more likely to feel that they are not reaching their full potential and thus, 
assess their QoL as being poorer. This is consistent with work by Bowie and colleagues 
(2007) which found that patients with better cognitive abilities tend to overestimate their 
level of disability.
Finally, we found that in the patient sample, although clinician assessed depressive 
symptoms were associated with subjective QoL, consistent with what was found for self-
reported depression, clinician assessed avolitional symptoms were not associated with QoL 
in the same way as self-reported avolitional symptoms. This finding suggests that clinicians 
and patients may differ in how they view avolitional symptoms. It is likely that this 
discrepancy, at least in part, is related to the specific scales used in the present study. 
However, it may also reflect fundamental differences between the objective narrative 
clinicians have, and the subjective narratives that patients have about psychiatric symptoms. 
Indeed, although some data suggests that severely ill patients are unable to accurately report 
negative symptoms (Hamera et al., 1996; Selten et al., 2000), more recent studies have 
suggested that self-report measures may be both valid and useful in this patient population 
(Dollfus et al., 2016), especially in the assessment of treatment outcome and overall QoL 
(Fleischhacker et al., 2005; Lindstrom et al., 2001; Ohata et al., 2014). Thus, the present 
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findings may add to a growing literature emphasizing the utility of self-reported symptoms 
in assessing patient-centered outcomes.
Several limitations of the present study should be noted. First, although the CAPE can be 
scored to produce subscale scores that reflect a dimensional assessment of negative 
symptoms, it was not specifically designed for this purpose. It should be noted, however, that 
the negative symptom subscale scores derived from the CAPE were highly correlated with 
their clinician-rated counterparts (all rho’s > .60; all p’s <.01). Nevertheless, future efforts 
seeking to examine the effects of different dimensions of negative symptoms on QoL should 
utilize more comprehensive measures of these constructs. Additionally, our analyses did not 
examine the effects of variation within the different cognitive domains assessed by the 
MCCB but rather, only examined the composite score as an index of global cognitive 
function. Given our patient sample size, however, the inclusion of all 7 domains captured by 
the MCCB in our analyses would have substantially reduced our power to detect any 
meaningful effects. Thus, using the composite score represented a compromise that allowed 
us to maintain adequate power while still addressing the more global contribution of 
cognitive function to QoL.
Despite these limitations, the results of the present study have several important 
implications. First, they suggest that even at subclinical levels, depressive and avolitional 
symptoms have a meaningful impact on the overall subjective QoL of those experiencing 
them. Second, these results complement recent work which finds an overlap in the risk 
factors associated with the development of both clinically-significant and subclinical 
symptoms (Linscott and van Os, 2013) and supports other work suggesting that they may 
also have similar consequences (DeRosse et al., 2014a; DeRosse et al., 2014b). These 
findings highlight the importance of addressing depressive and avolitional symptoms in the 
treatment of patients with schizophrenia spectrum disorders and suggest that improvements 
in these symptom domains may have a meaningful impact on their overall QoL. Finally, 
these findings collectively highlight the need for the type of approach championed by the 
Research Domain Criteria (RDoC) which calls for the recognition that most clinical 
problems cut across conventional diagnostic boundaries and exist along a dimension from 
healthy to various levels of pathological.
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Figure 1. 
Simple scatterplots illustrating the relationship between: a) global cognitive function as 
measured by the MCCB Composite score b) self-reported avolitional symptoms and c) self-
reported depressive symptoms (y-axes) and subjective Quality of Life (x-axes) in patients 
with schizophrenia or schizoaffective disorder (N=149) and healthy volunteers (N=408).
Abbreviations: QOLS: Quality of Life Scale (Burckhardt & Anderson, 2003); CAPE: 
Community Assessment of Psychic Experiences (Stefanis et al., 2002); MCCB: MATRICS 
Consensus Cognitive Battery (Neuchterlein et al., 2004)
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Table 1
Descriptive statistics and comparisons between the patients and healthy volunteers assessed in the present 
study.
Patient (N=149) Control (N+408) Statistic p value
Mean Age (SD) 40.61 (11.65) 39.50 (16.73) t=0.75 0.45
Percent Female 36.24 67.4 χ2=43.83 <.001
Race χ2=17.86
 White 67 257
 Black 61 61
 Other 21 55
Mean QOLS (SD)
 Total Score 79.20 (16.82) 92.95 (11.86) t=9.18 <.001
Mean CAPE (SD)
 Positive 32.25 (10.14) 23.35 (3.51) U=49,956 <.001
 Depressive 14.53 (4.26) 11.25 (2.20) U=45,145 <.001
 Social Withrawal 5.15 (1.73) 4.00 (1.23) U=43,033 <.001
 Flat Affect 4.88 (2.01) 3.53 (0.93) U=43,222 <.001
 Avolition 14.47 (4.81) 10.78 (2.56) U=45,202 <.001
Mean Clinician-based (SD)
BPRS Psychosis 5.83 (2.85) n/a n/a n/a
HRSD-24 12.8 (7.34) n/a n/a n/a
SANS Global Asociality/Anhedonia 2.17 (1.13) n/a n/a n/a
SANS Global Affective Flattening 1.85 (1.26) n/a n/a n/a
SANS Global Avolition 2.50 (1.12) n/a n/a n/a
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Table 2
Regression results for healthy volunteers (top) and patients (middle) in which models included self-reported 
symptoms. The bottom segment of the table presents the regression results for the same set of patients in 
which the model replaced self-reported symptoms with clinician assessed symptoms.
Final Model Variable β t p value
Controls Age 0.002 0.03 0.976
Sex 0.08 0.98 0.33
MCCB Composite 0.12 2.42 0.02
CAPE Positive 0.19 2.02 0.05
CAPE Depressive −0.26 2.44 0.02
CAPE Social Withdrawal −0.18 1.99 0.05
CAPE Flattened Affect 0.14 1.46 0.15
CAPE Avolition −0.42 3.46 0.001
Patients Self-Report Age −0.14 1.73 0.09
Sex 0.02 0.28 0.78
MCCB Composite −0.17 2.02 0.05
CAPE Positive 0.08 0.83 0.41
CAPE Depressive −3.27 −2.6 0.01
CAPE Social Withdrawal 0.12 1.13 0.26
CAPE Flattened Affect 0.01 0.08 0.94
CAPE Avolition −0.32 2.1 0.04
Patients Clinician Assessments Age −0.18 2.09 0.04
Sex 0.03 0.34 0.74
MCCB Composite −0.28 3.16 0.002
BPRS Psychosis 0.07 0.8 0.42
HRSD-24 −0.39 4.03 <.001
SANS Global Asociality/Anhedonia −0.13 1.31 0.19
SANS Global Affective Flattening −0.05 0.59 0.55
SANS Global Avolition −0.06 0.61 0.54
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